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ABSTRACT 
Myotonic dystrophy type 1 (DM1) is caused by a CTG repeat expansion located in the 3’ 
untranslated region of the DMPK gene. Expanded DMPK transcripts aggregate into nuclear foci 
and alter the function of RNA-binding proteins, leading to defects in the alternative splicing of 
numerous pre-mRNAs. To date, there is no curative treatment for DM1. Here, we investigated a 
gene editing strategy using the clustered regularly interspaced short palindromic repeat 
(CRISPR)-Cas9 system from Staphylococcus aureus (Sa) to delete the CTG repeats in the human 
DMPK locus. Co-expression of SaCas9 and selected pairs of single guide RNAs (sgRNAs) in 
cultured DM1 patient-derived muscle line cells carrying 2600 CTG resulted in targeted DNA 
deletion, ribonucleoprotein foci disappearance and correction of splicing abnormalities in various 
transcripts. Furthermore, a single intramuscular injection of recombinant AAV vectors 
expressing CRISPR-SaCas9 components in tibialis anterior muscle of DMSXL mice decreased 
the number of pathological RNA foci in myonuclei. These results establish the proof of concept 
that genome editing of a large trinucleotide expansion is feasible in muscle, and may represent a 
useful strategy to be further developed for the treatment of myotonic dystrophy. 
 
 
Keywords: CRISPR-Cas9; DMPK; gene therapy; myotonic dystrophy; nucleotide repeat 
disorders 
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INTRODUCTION 
Myotonic dystrophy type 1 (DM1) is the most common form of adult muscular dystrophy, with 
an estimated prevalence of 1 in 8,000 individuals. The disease is autosomal dominant and 
characterized by multisystemic symptoms like myotonia, muscle weakness, cardiac conduction 
defects, cataracts, insulin resistance and cognitive abnormalities 
1
. DM1, also called Steinert 
disease, is caused by a CTG repeat expansion in the 3’ untranslated region (UTR) of the DMPK 
gene coding for a serine/threonine kinase that is mainly expressed in smooth, skeletal and cardiac 
muscles 
2-7
. 
The number of DMPK CTG repeats usually ranges from 5 to 37 in unaffected individuals, and 
from 51 to several thousands in DM1 patients 
1
. The length of the expansion correlates with 
clinical severity and inversely to disease onset. Expanded CTG repeats are unstable in the 
germline, leading to the phenomenon of anticipation in members of the same family, i.e. 
occurrence of the disorder at progressively earlier ages in successive generations, and in somatic 
cells, resulting in high levels of mosaicism among different tissues, which plays a primary role in 
DM1 severity 
8-10
. 
Several in vitro and in vivo studies elucidated the disease mechanism, which is mainly mediated 
by a toxic gain-of-function of RNA transcripts (for review see 
11
). Transcription of mutated 
DMPK generates mRNAs with long CUG repeats, which accumulate in the nucleus and form 
stable ribonucleoprotein aggregates called foci, interfering with at least two antagonistic protein 
families that regulate alternative splicing, the muscleblind-like (MBNL) and CUGBP/Elav-like 
(CELF) protein family 
11, 12
. Splicing regulators of the MBNL family, which are able to bind 
C/CUG sequences, are sequestered within the foci, and therefore functionally downregulated 
13
, 
and CELF proteins are upregulated through protein stabilization 
14, 15
. These alterations result in 
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aberrant expression of embryonic splicing profiles in adult tissues; forty-two mispliced events 
were validated in muscle of DM1 patients, such as for the insulin receptor (IR) and cardiac 
troponin T (cTNT), and subsequent cellular dysfunction 
16-20
. 
Several approaches that act at different levels of the pathological cascade, mainly targeting 
mutated DMPK transcripts, have been investigated but no efficacious treatment is currently 
available for DM1 patients (see review 
21
). The experimental therapies that have been addressed 
include: i) degradation of mutated DMPK transcripts by small nuclear antisense RNA 
22, 23
, 
gapmer antisense oligonucleotides (ASOs) 
24
, an artificial RNA endonuclease 
25
, or deactivated 
Cas9 nuclease (dCas9) 
26
; ii) viral vector-mediated Mbnl1 overexpression 
27
; and iii) interference 
with foci formation through antisense morpholino oligonucleotides (MOs), small molecules and 
peptides that disrupt MBNL1-C/CUG interaction 
28-30
. A gapmer ASOs (IONIS-DMPKRx), 
based on RNase H-mediated degradation of heteroduplex ASO-DMPK RNA, was tested in a 
phase 1/2a clinical trial in adult patients with DM1 (https://clinicaltrials.gov/; NCT02312011), 
and, although well tolerated, the drug levels in muscle did not achieve the desired therapeutic 
benefit. 
Gene editing represents an alternative strategy to correct mutations responsible for inherited 
disorders. The CRISPR-Cas9 system, identified in bacteria as part of the bacterial immune 
system 
31
, is a powerful tool that has been adapted for medical applications 
32, 33
. Recent studies 
demonstrated that delivery of recombinant adeno-associated viral (rAAV) vectors expressing 
CRISPR-Cas9 components was able to restore dystrophin expression in muscles of Duchenne 
muscular dystrophy mouse models 
34-36
, opening new frontiers for the cure of neuromuscular 
disorders (see review 
37
). 
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Here, we investigated CRISPR-Cas9 from Staphylococcus aureus (Sa) to identify sgRNAs 
capable of cutting efficiently regions flanking the DMPK CTG repeat. SaCas9 is a small size 
nuclease that fits into a rAAV vector and may have high cleavage activity in human cells 
38
. We 
performed experiments in DM1 patient-derived immortalized myoblast cells and observed an 
efficient deletion of the CTG repeat tract for a pair of sgRNAs, leading to stable absence of 
nuclear foci and reversion of splicing abnormalities. Notably, no mutations were found in 
potential off-targets of each sgRNA. Next, we evaluated this CRISPR-Cas9 approach in DMSXL 
mice, a DM1 mouse model carrying a human DMPK gene with ~1200 CTG repeats under the 
regulation of its own promoter 
39, 40
. Our results show that a single intramuscular injection of two 
rAAV9 vectors, expressing the nuclease SaCas9 and the most efficient pair of sgRNAs, were 
also able to delete the CTG repeat in muscle fibers. Consequently, a reduction in the number of 
myonuclei containing pathological ribonucleoprotein foci was observed. This study represents 
the first proof-of-concept of in vivo genome editing for DM1 and, with further development, 
provides novel perspectives for the treatment of nucleotide repeat disorders that affect muscles. 
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RESULTS 
CRISPR-Cas9 Strategy for DM1 Disease 
To selectively remove the CTG repeat expansion of the DMPK gene, we initially used the 
CRISPR-Cas9 system from Neisseria meningitidis (Nm) 
41
, as the size of NmCas9 is small and 
suitable for vectorization in rAAV vectors. We selected four sgRNAs that target regions flanking 
the CTG repeat and tested their deletion efficiency in HeLa cells (Figure S1, 
42
). PCR 
amplification of the DMPK genomic region encompassing the sgRNA target sites resulted in 
very weak intensity bands of the deleted fragments compared to the undeleted PCR products, 
suggesting a low cutting efficiency for NmCas9 (Figure S1C).  
Based on these results, we pursued this study by testing the CRISPR-Cas9 system from 
Staphylococcus aureus (Sa) 
43
, which also encodes a small size nuclease. We restricted the target 
region to the portion of the DMPK 3’ UTR between the stop codon of the gene and the 
polyadenylation signal, to avoid interference with the coding sequence and mRNA maturation. 
First, we selected 15 sgRNAs targeting this region and used HeLa cells for screening. We 
quantified the frequency of indels (insertions and deletions) by PCR amplification and 
sequencing of the respective sgRNA genomic targets, followed by TIDE analysis 
(https://tide.nki.nl/), a method based on the recovery of indels spectrum from the sequencing 
chromatogram to quantify the proportion of templated editing events, including point mutations 
44
. The sgRNAs binding the region upstream the CTG repeat (Figure 1A; Table S1; sgRNA 1, 4, 
7 and 8) induced indels at high frequencies, with values between 42% and 47%. However, 
downstream sgRNAs resulted in scattered indel values that ranged from 1% to 48.3%. For 
sgRNA 12, 13 and 17, we generated two versions of the protospacer, with either 21 (sgRNA 
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12A, 13A, 17A) or 24 (sgRNA 12B, 13B, 17B) nucleotides. Interestingly, the cutting efficiency 
of the shorter sgRNAs 12A and 13A was higher than the longer forms.  
In order to test the ability of sgRNA couples to delete the CTG repeat, we generated constructs 
expressing SaCas9 and two sgRNAs in tandem, targeting upstream and downstream regions of 
the repeat. Based on the best single cutting efficiency (Table S1), we selected 4 sgRNAs 
targeting each side of the CTG repeat, and assorted them in 16 couples (Figure 1A, sgRNA 
targets in black). We tested these constructs in HeLa cells by transfection and performed 
genomic PCR analysis using primers F and R, which anneal regions upstream and downstream 
the more distant sgRNAs 1 and 23 (Figure 1A; Table S4). PCR fragments with deleted CTG 
repeats were observed for all sgRNA couples (Figure 1B, bands of ~0.2-0.8 kb, black arrow); 
only two couples, 1-13A and 1-23, showed deleted PCR products of weaker intensity. Notably, 
the intensity of the undeleted bands compared to the edited fragments was negligible (Figure 1B, 
band of ~0.9 kb, white arrow), indicating that the selected sgRNA couples drive efficient 
deletion of the CTG repeat flanking regions.  
 
Genome Editing of DMPK CTG Repeats in Human DM1 muscle cells  
Next, we aimed to test the ability of CRISPR-SaCas9 to delete a pathogenic CTG repeat 
expansion. We chose as DM1 in vitro model, an immortalized myoblast cell line derived from a 
patient carrying 2600 CTG repeats in the DMPK gene 
45
. This cell line reproduces the most 
important cellular hallmarks of the disease, in particular, presence of nuclear foci and splicing 
defects in various transcripts. 
As these myoblasts were hardly transfected (about 30% for a control GFP plasmid), we delivered 
CRISPR-SaCas9 by lentiviral vectors, which are known to infect with high efficiency cultured 
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muscle cells. In particular, we designed a dual vector system to test various combinations of 
sgRNAs with SaCas9 (Figure 2A). Taking into consideration the following criteria for each 
sgRNA: 1) individual frequency of indels at the target site, 2) number of predicted off-targets 
and 3) distance of the target site to the CTG repeat extremities, we selected couples 4-23, 4-12A, 
8-12A and 8-23 for in vitro studies (Figure 1A and 1B; Table S1). DM1 patient-derived muscle 
line cells were transduced with increasing equal MOI (multiplicity of infection) of both SaCas9 
and sgRNAs lentiviral vectors, and deletions of the CTG repeat region were analyzed by 
genomic PCR from the bulk cell population (Figure 2B). All four sgRNA couples were able to 
delete the targeted region, although 4-23, 4-12A, and 8-23 appeared more efficacious as the 
deleted band was visible at low MOI (Figure 2B; faint band at MOI=5). The amount of edited 
PCR fragments increased proportionally to the MOI tested. To notice, the expanded allele was 
not PCR amplified due to the size of the 2600 CTG repeat (corresponding to a >8 kb fragment). 
Thus, we estimated the percentage of CTG repeat deletion by comparing the intensity of edited 
products, originating from the two alleles, to that of undeleted bands from the normal allele 
(Figure 2C; % DEL), and sgRNA couple 4-23 appeared as the most efficient one in deleting the 
targeted genomic region (Figure 2B and 2C).  
We then monitored the presence of nuclear foci in lentiviral-transduced DM1 myoblasts by 
fluorescent in situ hybridization (FISH) with a (CAG)7 probe. CRISPR-SaCas9-mediated 
deletion of the expanded CTG repeat region resulted in a reduction and/or completely 
disappearance of nuclear foci in treated cells. In particular, the percentage of cultured DM1 cells 
without foci was higher in presence of sgRNA couple 4-23 and reached 19.2 and 27.5% at MOI 
50 and 100 versus 4.4% and 6.2% for cells treated only with one of the two lentiviral vectors 
(Figure 2D). The other couples of sgRNA resulted in similar (sgRNA 4-12A) or lower (sgRNA 
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8-23 and 8-13A) percentage of cells without foci (Figure S2). Overall, these data demonstrate the 
ability of the selected sgRNAs to delete CTG repeats from the 3’ UTR of the DMPK gene, and 
likely from the pathogenic expanded allele. 
To better analyze genome editing events in DM1 cells, we isolated and characterized myoblast 
clones transduced with MOI 50 of lentiviral vectors expressing SaCas9 and sgRNA4-23-GFP. We 
analyzed 50 GFP positive clones by FISH and identified 5 clones negative for the presence of 
nuclear foci, which were also positive for the expression of SaCas9 (Figure 3A, DM1-Delta). 
DM1 clones expressing only SaCas9 (DM1-Cas9) or sgRNAs 4-23 (DM1-sgRNA), and non-
transduced cells were used as controls. We selected several DM1-Delta clones (10, 3, 17 and 22) 
for further analysis, and confirmed by genomic PCR the deletion of the CTG repeat in the 
DMPK locus (Figure 3B). For clones 10 and 3, only one PCR fragment was amplified, 
suggesting a biallelic deletion, whereas for clones 17 and 22, undeleted (upper band) and deleted 
(lower band) PCR products were observed. The intermediate bands observed in the gel for clones 
17 and 22 are heteroduplexes of PCR amplicons with and without CTG repeat deletions, as 
shown by denaturation and renaturation of a mixture of PCR amplicons (Figure S4). Sequencing 
of the shorter PCR fragments from the four clones (Figure 3B, band of ~0.4-0.5 kb) confirmed 
the complete deletion of the CTG repeat for clones 10, 17 and 22, and a partial deletion with 8 
remaining nucleotides of the CTG repeat and the upstream 99 nucleotides of the genomic 
sequence for clone 3 (Figure 3C and 3D). To notice the cutting and joining position was not 
always at position between nucleotide N3 and N4 upstream the PAM sequence, as a variable 
number of nucleotides upstream the expected cutting sites was deleted. In addition, longer PCR 
products of DM1-Delta clones 17 and 22 (Figure 3B, upper band of ~1 kb) revealed 
microdeletions of variable length, including the PAM sequence, in the target sites but intact 
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unexpanded CTG repeat (Figure 3D). These results suggest that non-synchronized cuts occurred 
at each target site of the normal DMPK allele, which were repaired by non-homologous end-
joining (NHEJ), and the expanded allele was properly edited. Control DM1-sgRNA clones, still 
containing nuclear foci, did not show any indels at the target sites (Figure 3D). Interestingly, we 
did not find off-target indels in DM1-Delta clones (see Supplemental Information). 
In order to have a clear evidence of the deletion of the expanded CTG repeat in the DMPK gene, 
we performed southern blot analysis on EcoRI digested genomic DNA, which was hybridized 
with a probe annealing a 1.4 kb region of the DMPK 3’ UTR (Figure 3E). In DM1 cells, the 
presence of 2600 CTG repeats in the expanded allele (CTGexp), and 13 CTG in the normal allele 
(ctg), resulted in two fragments of 17.4 and 8.6 kb, respectively, compared to 9.6 and 8.6 kb 
bands in immortalized myoblasts from a control individual (Ctrl) containing 5 and 14 CTG 
repeats. In all three DM1-Delta clones analyzed, the genomic excision of the expanded CTG 
repeat region was revealed by the absence of the 17.4 kb EcoRI band in the southern blot (Figure 
3F and 3G). Moreover, because of the presence of a 1 kb Alu polymorphism in the CTGexp allele 
but not in the normal allele of this DM1 cell line 
46
, it was possible to distinguish the edited 
fragments originating from the expanded (∆CTGexp, 9.1 kb) and normal (∆ctg, 8.1 kb) alleles. 
Thus, southern blot analysis confirmed a biallelic deletion in clone 10 (∆CTGexp/∆ctg; 9.1 kb and 
8.1 kb bands), and a monoallelic deletion in clones 17 and 22 (∆CTGexp/ctg; 9.1 kb and 8.6 kb 
bands). Altogether, these results show that CRISPR-SaCas9 is able to excise expanded CTG 
repeats in the DMPK 3’ UTR of human DM1 cells. To notice, in clones 17 and 22 the two EcoRI 
fragments corresponding to deleted expanded CTG (∆CTGexp) and undeleted unexpanded CTG 
(ctg) appeared as a unique diffused band instead two well-separated bands because they differ 
only ~ 0.5 kb. 
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Correction of Alternative Splicing Defects in DM1 Edited Muscle Cells 
Sequestration of MBNL splicing factors in nuclear foci of DM1 cells leads to alterations in the 
alternative splicing of numerous pre-mRNAs, some of which are reproduced in differentiated 
muscle cells in culture 
45
. We therefore assessed the splicing pattern of LIM domain binding 3 
(LDB3) exon 11, Sarco/endoplasmic reticulum calcium ATPase 1 (ATP2A1) exon 22, 
Muscleblind like splicing regulator 1 (MBNL1) exon 7, Duchenne muscular dystrophy (DMD) 
exon 78, insulin receptor (IR) exon 11 and Bridging integrator 1 (BIN1) exon 11 in edited DM1-
Delta clones compared to DM1, DM1-sgRNA, and control (Ctrl) cells (Figure 4). RT-PCR 
analyses revealed that the splicing profile of these transcripts in DM1-Delta myotubes was 
significantly different than in untreated DM1 cells, and in general comparable to control 
myotubes, with some variations for MBNL1 and BIN1 splicing in clone 10. Therefore, CRISPR-
SaCas9-mediated excision of the expanded DMPK CTG repeat region resulted in the correction 
of the splicing defects of DM1 cells. Interestingly, the levels of DMPK mRNA after CTG 
deletion in DM1-Delta clones were similar or even higher than in untreated DM1 cells (Figure 
S5A), suggesting that the excision of the CTG repeat in the 3’UTR  did not affect the stability of 
this transcript. 
 
Deletion of Expanded CTG Repeats in Muscle Fibers of DMSXL Mice  
To assess whether the CRISPR-SaCas9 system was able to delete the CTG repeats in vivo, we 
performed experiments in DMSXL transgenic mice, a mouse model of myotonic dystrophy type 
1 that carries a copy of the human DMPK gene with ~1200 CTG repeats in the 3’ UTR, and 
exhibits features of the disease, such as presence of nuclear RNA foci in muscles 
47
. We 
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generated serotype 9 rAAV vectors (rAAV9), which are known to transduce efficiently 
myofibers 
48
, containing expression cassettes for either SaCas9 under the muscle-specific SPc5-
12 promoter or the couple of sgRNAs 4-23 under the U6 promoter (Figure 5A).  
First, we evaluated the feasibility of this approach by intramuscular delivery of the vectors in 
heterozygous DMSXL mice at various doses and ages, as these mice do not display the high 
mortality rate observed in homozygous mice. A combined dose of 0.6 x 10
11
 viral genomes (vg) 
and
 
1 x 10
11 
vg was injected into the left tibialis anterior (TA) muscle of  HTZ mice at 3 and 6 
weeks of age, respectively (the injected dose contained a mixture of equal vg of each vector per 
muscle). The contralateral TA muscle was injected with equivalent volume of PBS as control. 
The effect of vector administration was analyzed 4 weeks post-injection, and hematoxylin and 
eosin (H&E) staining of TA sections did not reveal signs of muscle degeneration (only few and 
small foci of inflammatory infiltrates were observed in muscles of 2 out 7 mice of the older 
group of treated animals, data not shown). To evaluate CRISPR-SaCas9 activity in muscles, we 
PCR amplified the targeted genomic region from the two groups of animals. PCR amplicons 
corresponding to the edited fragment (0.4 kb) were detected in TA muscles co-injected with 
rAAV9-SaCas9 and rAAV9-sgRNA4-23, but not in the contralateral PBS-injected muscles 
(Figure S3A). Moreover, a specific PCR protocol was used to amplify the genomic region 
containing the undeleted CTG repeats (4.5 kb), which was detected only in PBS-injected TA 
(Figure S3B).  
Based on these results, we evaluated whether administration of SaCas9- and sgRNA4-23-
expressing vectors could also delete the CTG repeat expansion in muscles of homozygous 
(HMZ) DMSXL mice, and correct pathological signs of the disease. For that purpose, rAAV9 
vectors were delivered intramuscularly at a dose of 1 x 10
11 
total vg in the left TA muscle of 5-9 
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week-old homozygous mutant mice, and an equal volume of PBS was injected in the 
contralateral muscle. Four weeks after injection, immunofluorescence analysis showed, as 
expected, the localization of SaCas9 within nuclei of muscle fibers (Figure 5B). The eGFP-K 
reporter that localizes to the membrane of myonuclei was used to visualize indirectly sgRNA 
expressing nuclei. In AAV-treated muscles, 21% and 76% of myonuclei were positive for 
SaCas9 and GFP, respectively, and 18% were positive for both. The relatively low percentage of 
SaCas9 positive myonuclei was similar by using anti-HA tag and anti-SaCas9 antibodies (data 
not shown). Since the same dose of each vector was injected in muscles, these results suggest 
that the sensitivity of antibodies against the HA tag or SaCas9 by immunohistology were quite 
low. H&E staining of muscle cross-sections from HMZ mice indicated the absence of significant 
damages in muscle tissue (only small foci of inflammatory infiltration in 1 out of 10 
homozygous, and 1 in 5 wild type mice, data not shown). PCR amplification of the DMPK 3’ 
UTR region resulted in small fragments corresponding to deleted CTG repeats, which was also 
confirmed by Sanger sequencing (Figure 5C and 5D). Interestingly, in muscle the target site was 
cut at nucleotide N3 upstream the PAM sequence, contrary to more variable cutting positions 
observed in edited DM1 cells in culture (Figure 5E and 3D). In order to further investigate the 
cutting pattern of SaCas9-sgRNA4-23 in DMSXL skeletal muscle, we performed deep sequencing 
analysis of PCR amplicons from 8 DMSXL HMZ mice, and compared the results to that 
obtained from the bulk population of cultured DM1 myoblasts transduced with lentiviral vectors 
expressing the same CRISPR-Cas9 components, and appropriate controls  (Figures 6A-C). PCR 
amplicons were encompassing the CTG repeat deletion (DEL) and the sgRNA4 or sgRNA23 
target sites (sgRNA4 and sgRNA23) depending on whether the repeat deletion had occurred or 
not. We found that the percentage of reads with indels was lower in skeletal muscle compared to 
14 
 
cultured cells, 9.6% versus 44.7% in DEL, 7.6% versus 30.8% for sgRNA4 and 6.3% versus 
17.3% in sgRNA23, respectively. These results suggest that CRISPR-SaCas9-mediated genome 
editing results in low levels of indels in skeletal muscle. 
Finally, we analyzed the effect of genomic CTG repeat deletion in DMPK mRNA levels and 
found that transcript levels did not change in tibialis anterior muscle treated with SaCas9-
sgRNA4-23 compared to the contralateral uninjected muscle (Figure S5B). 
 
Reduction of nuclear foci in genome edited DM1 skeletal muscle 
Next, we assessed the effect of CRISPR-SaCas9-mediated deletion of expanded CTG repeats in 
RNA foci of myonuclei from DMSXL mice. For that purpose, we analyzed tibialis anterior 
muscle cross-sections by FISH using the (CAG)7 probe and laminin immunostaining (α-LMN) 
to clearly delimit the basal lamina of muscle fibers and distinguish between nuclei located inside 
from outside myofibers (Figure 7A). Analysis of confocal images showed a statistically 
significant reduction of myonuclei containing foci in rAAV9-treated TA muscle. The percentage 
of nuclei with foci located in muscle fibers decreased by 24.17% four weeks after co-delivery of 
rAAV9-SaCas9 and rAAV9-sgRNA4-23 compared to PBS-injected contralateral muscles (Figure 
7B; P < 0001; N=10 mice). The number of myonuclei per fiber, calculated as ratio between total 
number of myonuclei and myofibers, was similar between treated and untreated TA muscles 
(Figure 7C; WT-PBS: 0.94±0.22; WT-AAV: 1.02±0.07; HMZ-PBS: 0.85±0.17; HMZ-AAV: 
0.75±0.15), indicating that the reduction of myonuclei containing foci in the group of rAAV9-
treated muscles resulted from the excision of expanded CTG repeats rather than changes in the 
total number of nuclei within myofibers. 
15 
 
In conclusion, we have shown that local administration of rAAV9 vectors expressing 
components of the CRISPR-Cas9 system can excise long CTG repeats in vivo and reduce 
pathological RNA foci within myonuclei of a mouse model of myotonic dystrophy type 1.  
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DISCUSSION 
The possibility of editing the genome has opened new perspectives for the treatment of inherited 
diseases. Here, we investigated whether the CRISPR-Cas9 system is efficient in correcting the 
genetic defect of myotonic dystrophy type 1 both in vitro and in vivo. Our study demonstrates 
that intramuscular administration of rAAV vectors that express Cas9 and selected sgRNAs in 
DM1 mice can excise the expanded CTG repeats in the human DMPK 3’ UTR and rescue 
pathological signs of the disease, establishing the first proof of concept that in vivo gene editing 
with active nucleases is feasible for DM1.  
We used CRISPR-Cas9 from Staphylococcus aureus to target the flanking regions of the CTG 
repeat tract and performed experiments in cultured cells to select the best sgRNA candidates for 
in vivo studies. We found that the genomic region downstream the CTG repeats was more 
difficult to cut than the upstream region. Among eight tested sgRNAs (plus three variants) only 
three of them, sgRNA 12A, 13A and 23, showed individual high indels frequencies (>30%) in 
cells. The region downstream the CTG repeats could be less accessible to the sgRNA-nuclease 
complex due to the presence of DNA secondary structures that may interfere with PAM 
recognition, sgRNA-DNA heteroduplex formation and/or Cas9 activity, as the conformation of 
the chromatin appears to influence CRISPR-Cas9-mediated genome editing, being more efficient 
in euchromatic than heterochromatic DNA regions 
49
. We selected 4 pairs of sgRNAs from 15 
designed sgRNAs that target the DMPK 3’ UTR to test gene editing in DM1 patient-derived 
immortalized myoblasts in vitro, and they were able to delete the targeted region with high 
efficiency, reduce nuclear RNA foci and revert the aberrant splicing of several transcripts. Other 
studies reported recently a similar approach by using CRISPR-Cas9 from Staphylococcus 
pyogenes (Sp) in cell cultures 
50-52
, however, the use of SaCas9 could be more advantageous for a 
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translational perspective as it is a smaller endonuclease that can be easily packaged into 
recombinant AAV vectors for in vivo studies. This would allow the inclusion of larger regulatory 
sequences in the expression cassette, which might be of interest for driving tissue-specificity of 
the nuclease activity, and/or sequences for sgRNA expression as all-in-one vectors. 
As alternative strategies, Gao and colleagues inserted a polyA signal upstream the DMPK CTG 
repeats in human DM1 induced pluripotent stem (iPS) cells by TALEN to prevent the 
transcription of toxic mutant transcripts, which resulted in foci disappearance and reversion of 
aberrant splicing in DM1 differentiated neural stem cells and cardiomyocytes 
53
. Genome editing 
has also been applied to contract and therefore shorten CTG trinucleotide repeats in cellular 
models by inducing either double-strand DNA breaks within the repeat tract with meganucleases, 
zinc-finger nucleases (ZNF) and transcription activator-like effector (TALE) nucleases (TALEN) 
54, 55
, or single-strand DNA breaks with a CRISPR-Cas9 D10A nickase in a GFP-based 
chromosomal reporter system 
56
. Finally, two other recent approaches exploited deactivated 
forms of Cas9, which do not cut DNA, to mediate inhibition of DMPK gene transcription 
57
 and 
degradation of toxic DMPK transcripts 
26
. The relevance of these various approaches for clinical 
translation and therapeutic intervention in patients with myotonic dystrophy type 1 remains to be 
assessed. 
So far, all DMPK gene editing studies with active nucleases were performed in cellular models 
or cells derived from DM1 patients. Here, we report that rAAV vectors expressing SaCas9 under 
the SPc5-12 muscle-specific promoter and U6-driven sgRNA 4 and 23 can excise the expanded 
repeat tract in skeletal muscle of DMSXL mice, which carry a human DMPK transgene with 
~1,200 CTG repeats 
39, 40
. The feasibility of genome editing in postnatal muscle was previously 
reported in mdx mouse models of Duchenne muscular dystrophy, a disease caused by mutations 
18 
 
in the large DMD gene 
34-36
. In these mice, CRISPR-Cas9-mediated NHEJ was able to remove 
the mutated exon 23 from the dystrophin gene with low cutting efficiency, which ranged from ~2 
% to 8 %, but resulted in the expression of a functional truncated dystrophin protein and 
significant increase in muscle fiber size and strength. In the context of a disease with a dominant 
form of inheritance and large nucleotide expansions, in vivo gene editing might be more 
challenging as therapeutic approach. Dual rAAV vectors expressing CRISPR-Cas9 components 
appeared more efficient than “all-in-one” single vector approaches in mice 
36, 58
. Therefore, in 
this study we administrated locally dual rAAV9 vectors into the tibialis anterior muscle of 
homozygous DMSXL mice when the pathology is already present. Four weeks after a single 
injection of 1.0 x 10
11 
total vg of vectors (0.5 x 10
10 
vg of each vector), SaCas9 and the sgRNA 
reporter GFP were expressed in the skeletal muscle with no or minimal inflammatory infiltrates, 
and resulted in the deletion of the expanded DMPK CTG repeat region. Deep sequencing of PCR 
products from the targeted genomic region revealed that the percentage of reads with indels was 
rather low (6% to 9%) in skeletal muscle of DMSXL HMZ mice compared to cultured DM1 
cells (17% to 44%), indicating that differences in DNA repair mechanisms between postmitotic 
myofibers and mitotic myoblasts exist. In addition, no indels were found in 20 potential off-
target sites of the selected sgRNAs. However, it has to be noted that a more comprehensive 
method, such as whole genome or exome sequencing, should be used in order to detect indels in 
other parts of the genome or other genomic modifications. Importantly, rAAV9-mediated 
CRISPR-SaCas9 delivery resulted in ~25% reduction in the number of myonuclei containing 
RNA foci, indicating that genome editing was efficacious in ameliorating a major 
histopathological hallmark of myotonic dystrophy. The splicing pattern of several transcripts (Ir, 
Ttn, Mbnl1 and Mbnl2) were found normal in tibialis anterior muscle of DMSXL mice 4 weeks 
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after injection of CRISPR-SaCas9 vectors, however these results are inconclusive as no 
significant differences were observed in the relative expression of the spliced variants of these 
genes in TA muscle between untreated mutant and WT mice (data not shown), reflecting the 
very mild splicing phenotype of DMSXL mice. Gene editing had also no effect at the level of TA 
muscle weight and strength in homozygous mutant mice under these conditions. This is in 
contrast with other gene editing studies in muscle, in particular for Duchenne muscular 
dystrophy, where an amelioration was observed at the level of muscle histology and/or function 
in animal models 
34-36, 58, 59
, and reflects probably the challenge of reducing toxic RNA levels in a 
gain of function disease like DM1 instead of increasing the amount of a functional protein in a 
recessive disease like DMD. The threshold of foci reduction in tissues and the age of treatment 
for DM1 phenotype correction remain to be elucidated. Interestingly, this gene editing approach 
could be used not only for muscle but also for other tissues affected in the disease by changing 
the promoter specificity of the Cas9 transgene and evaluating various routes of administration. 
In conclusion, we have established the proof-of-concept that CRISPR-SaCas9-mediated genome 
editing can efficiently delete the pathological CTG expansion from the human DMPK gene in 
vivo in skeletal muscle, and demonstrated that this approach can reduce RNA foci accumulation 
in myonuclei, which is a major pathological sign of the disease. Altogether, with further 
development, our study supports CRISPR-Cas9 based genome editing as a potential therapeutic 
approach for myotonic dystrophy type 1.  
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MATERIALS AND METHODS 
Plasmids and Design of sgRNAs 
The list of main constructs and primers employed in this study are reported in Tables S2 and S4.  
Plasmids were constructed with traditional cloning strategies using inserts PCR amplified, or 
synthetically synthetized, or sub-cloned upon enzymatic digestion of other existing constructs. 
Plasmid encoding for S. aureus Cas9 derives from plasmid pX601-AAV-CMV::NLS-SaCas9-
NLS-3xHA-bGHpA;U6::BsaI-sgRNA (MLS42, Addgene plasmid # 61591; 
43
). EFS promoter 
was PCR amplified from a plasmid containing EF1-alpha promoter with primers F-XhoI-MreI-
EFS (MLS63) and R-XmaI-NruI-EFS (MLS64) and cloned into XhoI/AgeI site of promoterless 
pX601-AAV-::NLS-SaCas9-NLS-3xHA-bGHpA;U6::BsaI-sgRNA to obtain pAAV-EFS::NLS-
SaCas9-NLS-3xHA-bGHpA;U6::BsaI-sgRNA (MLS43). 
The second cassette for sgRNA (U6::BbsI-sgRNA) was synthetically synthesized (GeneCust) 
using the same sequence of the existing cassette U6::BsaI-sgRNA of plasmid MLS42 but 
exchanging the sgRNA protospacer cloning site from BsaI into BbsI. Then, the BbsI cassette was 
cloned into Acc65I site of plasmid MLS43, upstream and in tandem the first sgRNA cassette, to 
obtain the construct pAAV-EFS::NLS-SaCas9-NLS-3xHA-bGHpA;U6::BbsI-sgRNA;U6::BsaI-
sgRNA (MLS47).  
Sa sgRNA protospacers, with n ID number, were synthesized as couple of oligonucleotides 
forward and reverse and in vitro annealed prior their cloning into the restriction sites BbsI or 
BsaI of plasmid MLS47, to obtain derivative plasmids pAAV-EFS::NLS-SaCas9-NLS-3xHA-
bGHpA;U6::n-DMPK-sgRNA;U6::BsaI-sgRNA and pAAV-EFS::NLS-SaCas9-NLS-3xHA-
bGHpA;U6::n(up)-sgRNA;U6::n(dw)-sgRNA_DMPK, this last with sgRNAs targeting upstream 
(up) and downstream (dw) the CTG repeat (see construct MLS93 as example). 
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SaCas9 target sequences within the DMPK 3’ UTR were screened by the programs CasBLASTR 
(http://www.casblastr.org/) and CRISPOR (http://tefor.net/crispor). The PAM sequence 
NNGRRT was used for the screening, with R= A or G (AYYCNN in the non-coding strand, with 
Y= T or C). 
For each sgRNA protospacer, the number of potential off-targets was calculated by the program 
CasOFFinder (http://www.rgenome.net/cas-offinder/) based on the human genome “Homo 
sapiens (GRCh38/hg38) - Human (02 April 2014 Updated). The selection of sgRNA 
protospacers was done taking into consideration the respective number of potential off-targets 
and their target position within the DMPK 3’ UTR region. Targets having potential off-targets 
carrying 3 or less mismatches were excluded. The length of the Sa sgRNA protospacer is 
between 21 and 24 nt. Whenever the protospacer did not start with a G, this nucleotide was 
added to the 5’ of the sequence to optimize the U6-driven transcription (Table S1). 
 
Cell Culture and Transfection Experiments 
HeLa cells were cultured in Dulbecco's modified Eagle medium (DMEM) with high glucose and 
GlutaMAX (Invitrogen), supplemented with 10% Fetal Bovin Serum (FBS, Invitrogen). 
Immortalized control (C25-Cl48, abbreviated Ctrl) and DM1 (DM11-Cl5) myoblasts were 
cultivated either in Skeletal Muscle Cell Growth Medium (Promocell) supplemented with 15% 
FBS, or in DMEM mixed to 199 medium (1:4 ratio; Life Technologies) and supplemented with 
20% FBS, 25 μg/ml fetuin, 0.5 ng/ml bFGF, 5 ng/ml EGF, 5 μg/ml insulin and 0.2 μg/ml 
dexamethasone (Sigma-Aldrich). Differentiation of myoblasts into myotubes was induced in 
confluent cells by replacing the growth medium with differentiation medium (DMEM 
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supplemented with 10 μg/ml insulin) for 5-6 days. Standard temperature of 37°C and 5% CO2 
were used to grow and maintain cells in culture.  
Cells were seeded the day before transfection in 6 or 12 well plates and transfected at 70-80% of 
confluence. Transfection reagent FuGENE HD (FuGENE-DNA ratio 3:1; Promega) was used to 
transfect HeLa cells. Cells were harvested by centrifugation 2-3 days post transfection and 
cellular pellet was kept at – 80°C until genomic DNA extraction. 
 
Lentiviral Vectors and Transduction Experiments 
Lentiviral vectors were constructed by cloning inserts U6::n(up)-sgRNA;U6::n(dw)-
sgRNA_DMPK into the XhoI/EcoRV site of a pCCL plasmid [pCC-hPGK.GFP (MLS87); gift 
from Dr. Mario Amendola] to obtain pCCL-U6::n(up)-sgRNA;U6::n(dw)-sgRNA_DMPK-
hPGK.GFP (see construct MLS100 as example). The CMV promoter, derived from plasmid 
MLS42, was cloned into the XhoI/AgeI site of promoterless pCCL-GFP (MLS87 without hPGK 
promoter) to obtain pCCL-CMV-GFP (MLS107). The construction of the lentiviral vector 
pCCL-CMV-SaCas9 (MLS110) was done by cloning SaCas9 PCR insert [primers F-AgeI-
SaCas9 (MLS142) and R-SalI-SaCas9 (MLS143); plasmid MLS42 as template] into SalI/AgeI 
site of pCCL-CMV (MLS107 without GFP).  
Lentiviral vectors were produced by calcium phosphate transient transfection of 293T cells as 
previously described 
60
. Vector titers [vector genome per ml (vg/ml)] were determined by 
quantitative PCR (qPCR) on genomic DNA of infected HCT116 cells (0.32 x10
9
 vg/ml for Cas9 
and 1-1.7 x10
9
 vg/ml for sgRNAs; virus production and titration by Genethon Vector Core and 
Quality Control Services, respectively). 
23 
 
For transduction studies, DM1 myoblasts were seeded the day before in 12 well plates and 
infected at 70% of confluence. Growth medium was removed before transduction and replaced 
with a minimal volume (400 µl/dish) of transduction medium [skeletal muscle basal medium 
(Promocell) or DMEM, supplemented with 10% FBS and 4 µg/ml polybrene]. Vectors were 
added directly to the transduction medium and cells were incubated for 5-6 hours before adding 
full growth medium. At day 1 post-transduction, cells were transferred to 6 well plates and kept 
in culture for two total passages before to 1) collect and freeze them for gDNA extraction, 2) fix 
them for fluorescence in situ hybridization and immunofluorescence analyses. 
 
rAAV Vectors and Animal Experimentation 
Recombinant adeno-associated virus (rAAV) vectors for SaCas9 and sgRNA couple 4-23 have 
been constructed by using pAAV plasmids [Genethon plasmid bank]. The small synthetic 
promoter SPc5-12, driving high expression of the transgene in muscle 
61
, was selected for the 
regulatory cassette of SaCas9, and human U6 promoter for both sgRNAs cassettes. SaCas9 was 
PCR amplified with primers F-PmeI-SaCas9 (MLS146) and R-NotI-SaCas9_3xHE (MLS147) 
and using plasmid MLS42 as template. Gel-purified insert SaCas9 was cloned into PmeI/NotI 
site of AAV plasmid pC512-Int-smSVpolyA (MLS1) in order to obtain pAAV-SPc5-12-SaCas9 
(MLS118). pAAV-Des-eGFP-KASH-U6::4-23-sgRNA_DMPK (MLS123) was obtained by 
cloning PCR insert U6::4-23-sgRNA_DMPK [primers F-MCS-before-U6SasgRNA (MLS163) 
and R-PmlI-EndSasgRNA-up (MLS166); plasmid MLS93 as template] into AflII/MssI site of 
pAAV-Des-eGFP-KASH (MLS23/MLS27). For production of rAAV9 vectors, the cis-acting 
plasmids expressing either SaCas9 or sgRNA, a trans-complementing rep-cap9 plasmid and an 
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adenovirus helper plasmid were co-transfected into HEK293 cells. Vector particles were purified 
and titrated as previously described 
62
.  
The transgenic DMSXL mouse line carrying a 45 kb expanded human DMPK genomic fragment 
was used in this study 
47
. Care and manipulation of mice were performed in accordance with 
national and European legislations on animal experimentation and approved by the institutional 
ethical committee. The genotype of the animals was assessed by PCR as previously described 
63
. 
The intramuscular injection of rAAV9 vectors was performed in ketamine/xylazine anesthetized 
WT, heterozygous and homozygous DMSXL mice at 3 to 9 weeks of age depending on the 
experiments. Equal amounts of the two vectors (1:1) were injected into the left tibialis anterior 
muscle (0.6 x 10
11
 total vg/TA at 3 weeks and 1 x 10
11 
total vg/TA in older mice; PBS was 
injected into the right TA as control. Four weeks post-injection, TA muscles were collected and 
frozen in liquid nitrogen for DNA and RNA extractions, or fixed in 4% PFA for 
FISH/immunofluorescence analyses. 
 
Genomic DNA Extraction and PCR 
Genomic DNA was extracted from HeLa cells and immortalized myoblasts either with GeneJet 
Genomic DNA purification Kit (Thermo Fisher Scientific) or with QIAmp DNA Micro and Mini 
Kit (QIAGEN), according to manufacturer’s instruction. PCR was performed with Platinum® 
Taq DNA Polymerase High Fidelity (Invitrogen) in presence of 150 ng of gDNA as template; in 
particular to amplify DMPK 3’ UTR, the PCR master mix was supplemented with 10% DMSO; 
primers MLS14 and MLS15 were used for the experiments shown in Figure 1B, 2B and S1C, 
and primers MLS14 and MLS17 for the other experiments (see primer list in Table S4). The 
PCR in Figure S3B was performed in presence of 2x DNA polymerase buffer, 38 cycles and 
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5min extension time in order to amplify the CTG repeat expansion present in DMSXL muscles. 
PCR products were separated by electrophoresis in a 1.5-2% agarose gel containing GelRed 
DNA stain. PCR products obtained by gel extraction or purification (NucleoSpin® Gel and PCR 
Clean-up, Macherey-Nagel) were sequenced by Sanger DNA sequencing (Beckman Coulter 
Genomics and Genewiz). 
 
FISH and Immunofluorescence 
Cultured cell analyses. FISH experiments were performed with the probe Cy3-labeled 2’OMe 
(CAG)7 (Sigma-Aldrich; 1:1000 dilution, 100 μM stock) as described by Taneja KL 
64
. Briefly, 
cells cultivated in chamber slides (Corning) were washed in phosphate-buffered saline (PBS) and 
fixed in 4% PFA. After fixation, cells were washed in PBS and stored in 70% ethanol at 4°C for 
at least 30 min. Cells were hydrated in PBS and incubated with the Cy3-(CAG)7 in hybridization 
buffer (40% formamide, 2x saline-sodium-citrate (SSC), 0.2% BSA). Cells were then washed 
before adding mounting solution containing DAPI (SouthernBiotech) and kept at 4°C. When 
FISH was coupled to immunofluorescence (IF), after hybridization, microscopy slides were 
washed several times before permeabilization in PBS/0.25% TritonX-100. SaCas9 was detected 
by antibodies directed against the HA tag epitope located at the C-terminus of the protein. 
Purified mouse monoclonal anti-HA tag (Covance) was used as primary antibody at dilution 
1/400 in 5% BSA and incubated for 1 hour and 30 min at RT. Goat anti-mouse 633 secondary 
antibody (Themo Fisher Scientific) was used at dilution 1/1000 in 5% BSA and incubated for 1 
hour at RT. 
Muscle analyses. For muscle analysis, TA muscles were collected and immediately fixed in 4% 
PFA, incubated in 15% sucrose solution and frozen in ice-cold isopentane. Frozen muscles were 
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cut in section of 8 μm and subject to FISH coupled to IF or to simply IF. FISH experiments were 
done with the same probe used for experiments in DM1 cells (Cy3-labeled 2’OMe; Sigma-
Aldrich) and protocol previously described 
65
. Briefly, slides were pretreated in a boiled Target 
Retrieval Solution (DAKO), and then washed several times, before a 5 min incubation in 
PBS/2% ice-cold acetone. After permeabilization, microscopy slides were incubated first in 2x 
SSC buffer/30% formamide for 10 min at RT, and then in hybridization buffer (2x SSC, 30% 
formamide, 0.02% BSA, 2 mM vanadyl ribonucleoside complex, 66 μg/ml yeast tRNA, Cy3-
(CAG)7 probe 1/150 dilution from 100 μM stock) for 2 hours at 37°C. After wash, slides were 
subject to IF and incubated with primary antibodies overnight at 4°C. In particular, rabbit 
polyclonal antibodies anti-laminin (Dako, Z0097) were used at 1/1000 dilution, rabbit polyclonal 
antibodies anti-GFP (Abcam, Ab6556) at 1/2000 and monoclonal antibodies anti-HA tag 
(Covance) at 1/100. Muscle sections were incubated with secondary antibodies at 1/1000 
dilution: Alexa Fluor 647 donkey anti-rabbit IgG (H+L) (Jackson ImmunoResearch) was used 
for laminin detection, Alexa Fluor 488 goat anti-rabbit IgG (H+L) (Invitrogen) for GFP, and 
Alexa Fluor 594 F(ab')2 goat anti-mouse IgG (H+L) (Invitrogen) for HA tag (Cas9). Slides were 
mounted with an antibleaching solution containing DAPI (Prolong Diamond Antifade Mountant 
with Dapi, Molecular probes) for microscopy image acquisition.  
Confocal microscopy. FISH-IF images were captured with a spectral confocal LEICA SP8 
scanning microscope (Leica Microsystems, Germany). We employed the following laser 
excitation wavelengths: 405 nm for DAPI, 552 nm for Cy3-FISH, 635 nm for laminin, 488 nm 
for GFP and 552 nm for HA-Cas9. Z-stack images were obtained from the stacking of 23 serial 
images with 0.45 µm interval. For each TA muscle section, a total of 16 Z-stack images were 
acquired and analysed by Leica Application Suite X software. Counting was performed manually 
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and nuclei outside the muscle fibers were excluded from the analysis. Images were processed 
either with Adobe Photoshop and/or with ImageJ software. 
 
Southern Blot Analysis 
Genomic DNA was extracted from control (Ctrl) and DM1 immortalized cell lines, and 
derivative clones as described above. Approximately 5 g of gDNA was digested with EcoRI 
restriction enzyme overnight at 37°C. Digested DNA was resolved on a 0.7% agarose gel for 16 
hours at 50V. After migration, agarose gel was incubated for 1 hour in 1M NaOH solution, to 
denaturate the DNA, and then for 2 hours in neutralization buffer (1M Tris, 3M NaCl pH 8.5). 
Genomic DNA fragments were transferred from gel to Genescreen Plus Hybridization membrane 
(Perkin Elmer) via capillary action in 6x SSC buffer, and cross-linked to membrane using the 
Stratalinker UV crosslinker. DNA was hybridized with 2 x 10
6 
cpm/ml of 1.4 kb BamHI probe 
(B1.4) covering the region of DMPK CTG repeat 
39
. Probe was pre-labeled with High Prime 
DNA labeling Kit (Sigma) and hybridization was performed at 68°C overnight in PerfectHyb 
Plus Hybridization buffer (Sigma) containing 50 g/ml Human Cot-1 DNA (Thermo Fisher 
Scientific). Signal was revealed by using Phosphorimager.  
 
RT-PCR for Alternative Splicing 
Cells and tissues were homogenized in TRIzol reagent (Life Technologies) using a FastPrep 
apparatus, and total RNA extraction was done according to manufacturer’s instructions. RT-PCR 
was performed as previously described 
45
. Briefly, 1 μg of total RNA was reverse transcribed by 
M-MLV reverse transcriptase (Life Technologies) and 1 µl of cDNA preparation was used for 
the PCR (KAPA2G Fast ReadyMix, Sigma) with primers listed in Table S4. PCR products were 
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separated by 2% agarose gel electrophoresis and visualized with GelRed DNA stain upon UV 
exposition. Optical density of each PCR band was quantified using ImageJ software and 
percentage of exon inclusion was calculated as [exon inclusion band/ (summa exon inclusion + 
exclusion bands)] x 100. 
qRT-PCR for DMPK mRNA analysis 
Total RNA was extracted from cells lysates and homogenized muscle tissues in TRIzol reagent 
(Life Technologies) according to manufacturer’s instructions. RNA was subject to DNase 
treatment to remove genomic DNA contamination (Ambio DNA-free
TM
 DNA Removal Kit, Life 
Technologies) and reverse-transcribed using random hexamers and RevertAid H minus Reverse 
Transcriptase (Fermentas) (100 and 500 ng of total RNA from cells and muscle tissues, 
respectively). Quantitative PCR was performed in a LyghtCycler 480 system (Roche) by using 4 
µl of 1/10 diluted cDNA, SybrGreen mix (ThermoScientific) and primers listed in Table S4. 
 
Deep sequencing 
Investigation of indels types and distributions was conducted by Illumina deep sequencing of 
PCR amplicons generated from DM1 cells treated with MOI 100 of lentiviral vectors expressing 
SaCas9 and sgRNA4-23, and from DMSXL TA muscles intramuscularly injected at 5-6 weeks 
of age with rAAV9 vectors expressing SaCas9 and sgRNA4-23. Untreated DM1 cells and TA 
muscle injected with PBS were used as controls. PCR amplicons of around 300 bp were 
generated by nested PCR: first PCR reaction was performed with a set of primers specific for the 
targets (F1-DMPK-3UTR and R2-DMPK-3UTR for the region containing the CTG repeat 
deletion; F1-DMPK-3UTR and R-DMPK bef CTG for the region surrounding the target of 
sgRNA 4; F-DMPK-149up-sgRNA23 and R2-DMPK-3UTR for the region surrounding the 
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target of sgRNA 23). Amplicons generated from the first PCR served as template for a second 
reaction, which was performed with a second set of primers annealing downstream the first set 
and containing Illumina adaptors at the 5’ end of the sequence (see Table S4). Row deep 
sequencing reads from Illumina PE sequencing (IGATech) were merged using PEAR (v0.9.6, 
using : -n 50 –v 20 –q 20 –t 20) 
66
, and NEXTERA adaptor trimmed using cutadapt (v1.18, using 
–e 0.2, -o 10 –q 20 –m 50) 
67
. Merged sequences were then submitted to CRISPRESSO2 for 
INDELS discovery (using --ignore-substitutions  --q 20) 
68
.  
 
Statistical Analysis 
All data are represented as mean ± SD. Statistical analyses were performed with two-tailed 
Student-t test, paired for untreated and treated TA muscles from mice of the same genotype, or 
unpaired and equal variance for TA muscles from mice of different genotype. Analysis of the 
RT-PCR data on myoblasts cell lines was also done with two-tailed Student-t test. Differences 
were considered to be statistically different at P *< 0.05; **<0.01; ***<0.001.   
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FIGURE LEGENDS 
Figure 1. CRISPR-SaCas9 Genome Editing to Target DMPK CTG Repeats. (A) Scheme of 
selected Sa sgRNA target sites located in the 3’ UTR of the DMPK gene between the stop codon 
(stop) and the polyadenylation signal (pA), flanking the CTG repeats [(CTG)n]; sgRNAs in 
black resulted in higher percentage of indels as assessed by TIDE (Table S1). (B) Genomic PCR 
analysis showing the deletion of the region flanking the CTG repeats in HeLa cells. Cells were 
transfected with plasmids expressing SaCas9 and the indicated sgRNA couples (combinations of 
sgRNAs downstream the CTG repeat region 12A, 12B, 13A, or 23, and sgRNAs upstream 1, 4, 
7, or 8). (NT): non-transfected cells; (-): SaCas9 expressing plasmid without sgRNA. White and 
black arrows indicate undeleted and deleted PCR amplicons, respectively. 
 
Figure 2. CRISPR-SaCas9 Lentiviral Vectors Delete CTG Repeats in DM1 patient-derived 
muscle line cells. (A) Scheme of lentiviral vector constructs containing SaCas9 and sgRNA 
sequences. LTR: long terminal repeat; CMV: cytomegalovirus promoter; NLS: nuclear 
localization signal; HA: human influenza hemagglutinin epitope; pA: polyadenylation signal; 
U6: human U6 small nuclear RNA (snRNA) gene promoter; sgRNAup: sgRNA sequence 
targeting regions upstream the CTG repeats; sgRNAdw: sgRNA sequence targeting regions 
downstream the CTG repeats; hPGK: human phosphoglycerate kinase gene promoter; GFP: 
enhanced green fluorescent protein. (B) PCR amplicons of the genomic region containing the 
CTG repeats in DM1 myoblasts transduced with increasing MOI of lentiviral vectors expressing 
SaCas9 and the indicated sgRNA couples. Triangle in gradient colors reflects the MOI, from 5 in 
white to 100 in black. A total MOI of 5, 10, 20, 50 and 100 was used for the two vectors at 1:1 
ratio. White and black arrows indicate undeleted and deleted PCR amplicons, respectively. 
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Genomic DNA from non-transduced cells (NT) and cells transduced with only one lentiviral 
vector (SaCas9 or sgRNA, MOI 50) was used as controls. (C) Percentage of DMPK CTG repeats 
deletion (% DEL) quantified from agarose gel images showed in panel B. (D) Percentage of 
DM1 myoblasts without nuclear foci visualized by FISH images after treatment with indicated 
MOI of lentiviral vectors SaCas9 and sgRNA couple 4-23. Histograms show average values 
from three independent biological replicates ± SD. Statistical analysis by two-tailed Student t-
test. *: P < 0.05; ns: not significant. 
 
Figure 3. Deletion of Expanded CTG Repeats and Foci Disappearance in DM1 Myoblasts 
Treated with CRISPR-SaCas9. DM1 myoblast clones were isolated from the bulk population 
after transduction with lentiviral vectors; isolated clones were analyzed for the presence of 
nuclear foci (A) and presence of DMPK CTG repeats (B to F). (A) FISH-IF images of a 
representative DM1 myoblast clone without foci (DM1-Delta clone 22); DM1 clones non-
transduced (DM1) or transduced with MOI 50 of a lentiviral vector expressing SaCas9 (DM1-
Cas9) or sgRNA4-23 only (DM1-sgRNA) were used as control. SaCas9 (α-HA) is shown in red, 
GFP in green, RNA foci in yellow [(CAG)7], and nuclei in blue (DAPI). Scale bar: 10 μm. (B) 
PCR analysis of DMPK 3’ UTR in DM1-Delta clones 10, 3, 17 and 22 amplified with primers 
F1-DMPK-3UTR and R2-DMPK-3UTR, annealing regions surrounding the cutting sites of 
sgRNA 4 and 23. Ctrl: control myoblasts; DM1: non-transduced DM1 clone; DM1-sgRNA: 
DM1 clone transduced with only lentiviral vector expressing sgRNA4-23. PCR amplicons with 
undeleted (a; white arrowhead) and deleted (b; black arrowhead) CTG repeats are shown. (C) 
Sequencing chromatograms of deleted PCR products of panel B from DM1-Delta clones 10, 3, 
17 and 22, showing resection of the CTG repeats and resulting DNA end-joining. (D) Sequence 
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alignment of deleted and undeleted PCR products of panel B of ~1 kb (a) and ~0.4 kb (b), 
respectively. Indels and/or deletions of the CTG repeats are indicated by dashes; nucleotide 
substitutions are in red. Target sequences of sgRNA 4 and 23 are indicated in blue and pink, 
respectively; PAM sequences are underlined; the CTG repeats region [(CTG)n] is highlighted in 
black. (E) Schematic representation of the DMPK gene and exon 15, indicating the relative 
positions of EcoRI cutting sites, the 1 kb Alu polymorphism (Alu) and the annealing region of 
probe B1.4. (F) Southern blot showing the genomic deletion of 2600 CTG repeats in DM1-Delta 
clones. Genomic DNA was digested with EcoRI and hybridized with probe B1.4 showed in 
panel E. Bands corresponding to the two alleles can be distinguished by size because the Alu 
insertion is 1 kb. (G) Number of CTG repeats [(CTG)n] in each allele of the DMPK gene, with 
(1) and without (2) the Alu insertion, and expected size of EcoRI bands, in control (Ctrl), DM1, 
DM1-Delta and DM1-sgRNA clones. ctg: non expanded CTG repeats; CTGexp: expanded CTG 
repeats; ∆: deletion of the CTG repeats; white and blue arrows: allele with and without the Alu 
insertion. 
 
Figure 4. Reversion of Splicing Abnormalities in DM1 patient-derived muscle cells by 
CRISPR-SaCas9 Deletion of Expanded CTG Repeats. Splicing profiles and quantification of 
LDB3 exon 11, ATP2A1 exon 22, MBNL1 exon 7, DMD exon 78, IR exon 11 and BIN1 exon 11 
containing transcripts in differentiated myoblasts from DM1-Delta clones 10, 3, 17 and 22 
compared to control (Ctrl), DM1, and DM1-sgRNA clones. Graphs show average values from 
independent biological replicates ± SD (N=6 for Ctrl and DM1, N=3 for the other samples). 
Statistical analysis by two-tailed Student t-test. *: P < 0.05; **: P < 0.01; ***: P < 0.001; ns: not 
significant; ˂ DL: below detection limit. 
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Figure 5. rAAV-mediated CRISPR-SaCas9 Delivery in Muscle of DMSXL Mice Results in 
Deletion of Expanded DMPK CTG Repeats. (A) Schematic representation of rAAV9 
constructs: the expression of SaCas9 and sgRNAs 4-23 is under the control of the SPc5-12 and 
U6 promoters, respectively. The sgRNA construct contains a eGFP-Kash reporter under the 
Desmin promoter (Desm). ITR: Inverted Terminal Repeat; SPc5-12: synthetic muscle-specific 
promoter; Int: intron; NLS: nuclear localization signal; HA: human influenza hemagglutinin 
epitope; pA: polyadenylation signal; eGFP-K: enhanced Green Fluorescent Protein fused to Kash 
peptide; U6: human U6 small nuclear RNA (snRNA) gene promoter. (B) Representative 
immunofluorescence images of tibialis anterior muscle cross sections from homozygous (HMZ) 
DMSXL mice 4 weeks after intramuscular injection of  CRISPR-SaCas9 rAAV9 vectors, 
showing expression of SaCas9 (α-HA, in red) and sgRNAs (eGFP-K, in green) within muscle 
fibers. DAPI was used for nuclear staining. 21% and 76% of myonuclei were positive for SaCas9 
and GFP, respectively, and 18% were positive for both. A higher magnification of myofibers 
from the upper panels (white boxes I., II. and III. in merged image) is shown in panels below. 
Scale bar: 50 μm in upper panels, 25 μm in panels I., II. and III. (C) Genomic PCR of DMPK 3’ 
UTR from nine homozygous DMSXL mice (HMZ 1 to 9) 4 weeks after injection of PBS (-) in 
the left TA muscle and rAAV9 vectors expressing SaCas9 and sgRNAs 4-23 (+) in the 
contralateral TA. The amplified band of ~0.4 kb corresponds to the edited PCR amplicons with 
deletion of 1200 CTG repeats. (D) Sequence of deleted PCR products showing the end-joining 
site (black arrowhead) of sgRNA targets 4 (blue) and 23 (pink) after double stranded breaks. (E) 
Alignment of unedited (DMSXL) and edited (∆) DMPK 3’ UTR sequences from genomic DNA 
showing the sharp cutting position at nucleotide N3 upstream the PAM of sgRNA 4 and 23.This 
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representative sequence was obtained after Sanger sequencing of PCR products from TA 
muscles injected with rAAV-SaCas9 and sgRNA 4-23 (number of TA analyzed is equal to 9). 
 
Figure 6. Indels examination in DM1 patient cells and DMSXL mice after treatment with 
CRISPR-Cas9. Genomic deep-sequencing of the DMPK 3’-UTR region with (DEL, primers F1-
R1) or without CTG repeat deletion (sgRNA4, primers F1-R2; sgRNA23, primers F2-R1). Indels 
analysis was performed by alignment with the sequence resulting from a cut between nucleotides 
N3 and N4 at targets 4 and 23 for PCR amplicons with CTG repeat deletion, or alternatively with 
the respective unmodified genomic sequence. (A) Percentage of reads with indels in bulk 
population of DM1 cells (DM1 bulk) and in TA muscle of DMSXL mice treated with CRISPR-
Cas9 (+). Untreated DM1 cells and TA muscle injected with PBS were used as negative controls 
(-). (B-C) Indels distribution upstream and downstream the expected cutting sites (0) in PCR 
amplicons with (DEL) and without CTG repeat deletion (sgRNA4 and sgRNA23) generated 
from gDNA of treated DM1 cells and of representative TA muscles containing the lowest and 
the highest percentage of reads with indels. 
 
Figure 7. CRISPR-SaCas9 Expression in DM1 Muscle Decreases Nuclear Foci. (A) 
Representative confocal images of a TA muscle section stained with antibodies against laminin 
(α-LMN, red), FISH [(CAG)7, yellow] and DAPI (blue) (upper panels) from HMZ DMSXL 
mice. TA muscle section from WT animal shows the FISH background. A higher magnification 
of myofibers from the upper panels (white box in merged image) is shown in panels below. 
Arrows indicate myonuclei with nuclear foci. Scale bar: 50 μm in upper panels, 25 μm in lower 
panels. (B) Percentage of myonuclei containing foci in TA muscle fibers from DMSXL mice 4 
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weeks after PBS (64.83±9.25%) or rAAV9-SaCas9 + rAAV9-sgRNA4-23 (49.25±8.42%) 
intramuscular injection. Data are represented as means ± SD (N=10 HMZ mice). Statistical 
analysis with two-tailed Student’s t test. ***: P < 0.001. (C) Total number of myonuclei per fiber 
in TA of wild-type (WT) and homozygous (HMZ) mice 4 weeks after injection of either PBS or 
rAAV9-SaCas9 + rAAV9-sgRNA4-23 vectors. Data are represented as means ± SD (N=3 for WT 
mice; N=10 for HMZ mice). Statistical analysis with two-tailed Student’s t test. ns: not 
significant.  
 







